HDM1005
Peptide
Evidence outlook · registrational
Type 2 Diabetes: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-08-28.
Also in development:Obesity · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07394114 NCT07394114 · Type 2 Diabetes Registry: NCT07394114 | 3 | Change from baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 36) 2027-08-28 | In progress: results expected 28 Aug 2027 | not yet graded | link ↗ |
View 1 more trial
NCT07417306 NCT07417306 · Type 2 Diabetes Registry: NCT07417306 | 3 | Change from baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 40) 2027-08-30 | In progress: results expected 30 Aug 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other GLP-1/GIP receptor (dual) drugs
Tirzepatide (Mounjaro), Tirzepatide (Zepbound), BGM0504, Brenipatide, enicepatide and 7 more. Compare all 13 GLP-1/GIP receptor (dual) drugs
This mechanism is crowded: 12 other tracked programmes target it, 2 of them ahead of this one.
This drug's own stage for Obesity: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HDM1005: this drug | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Liraglutide (Saxenda) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT02918279: Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54) NCT01557166: Change From Baseline in Apnoea-hypopnoea Index (AHI) (Week 0, Week 32): Liraglutide 3.0 mg -12.22 events/hour (Standard Deviation 23.34) vs Placebo -6.08 events/hour (Standard Deviation 25.9) | |
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination), Dopamine/norepinephrine transporter | not yet graded | NCT03374956: Change in Total Body Weight (baseline to 12 weeks): Intervention Group -7.7% (IQR -11 to -4.7) vs Control Group -6.5% (IQR -11 to -2.3) phase 3 result · pivotal pending | |
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | Partial signal | NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met. | |
| Orlistat (Xenical) | Approved | Small molecule | Pancreatic/gastric lipase | Weak signal | No reviewed efficacy summary in this indication | |
| Phentermine / Topiramate (Qsymia) | Approved | Small molecule | Noradrenergic/anticonvulsant (combination) | Reliable signal | NCT00553787: Percent Weight Loss From Baseline to Week 56 (Baseline to 56 weeks): VI-0521 Mid 7.81% (Standard Error 0.365) | VI-0521 Top 9.84% (Standard Error 0.275) vs Placebo 1.24% (Standard Error 0.277) NCT00554216: Percent Weight Loss From Baseline to Week 56 (baseline to 56 weeks): VI-0521 Low 5.1% (Standard Error 0.538) | VI-0521 Top 10.92% (Standard Error 0.392) vs Placebo 1.55% (Standard Error 0.395) | |
| Semaglutide (Wegovy Tablets) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Semaglutide (Wegovy) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 NCT03548935: Change in Body Weight (%) (Baseline (week 0) to week 68): Semaglutide 2.4 mg — In-trial observation period: -15.6% (Standard Deviation 10.1); On-treatment observation period: -16.9% (Standard Deviation 9.4) vs Placebo — In-trial observation period: -2.8% (Standard Deviation 6.5); On-treatment observation period: -3.1% (Standard Deviation 6.4) | |
| Setmelanotide (Imcivree) | Approved | Peptide | MC4R | Weak signal | NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) NCT03287960: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 45.5% (95% CI 19.96 to 72.88) | |
| Tirzepatide (Zepbound) | Approved | Peptide | GLP-1/GIP receptor (dual) | Reliable signal | NCT05412004: Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21) NCT04660643: Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88): Tirzepatide MTD -6.7 percent change (Standard Error 0.52) vs Placebo 14.8 percent change (Standard Error 0.53) | |
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | NCT06703021: Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) | |
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | NCT07002905: Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo | |
| Berobenatide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | NCT06712836: Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). | |
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Partial signal | NCT06973681: Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity) | |
| Bofanglutide | Phase 3 | Peptide | GLP-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Cagrilintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | Reliable signal | NCT03856047: Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2) | |
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual) | Reliable signal | NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) NCT05813925: Change in body weight at week 68: -18.4% (SE 0.7) CagriSema vs -11.9% (SE 0.7) semaglutide alone; ETD -6.5 percentage points (95% CI -8.4 to -4.6; p<0.0001) | |
| DA-302168S | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | Reliable signal | NCT05813795: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met. | |
| Efmedaglutide Alfa (Shanmeining) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | Partial signal | NCT05997576: Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025). | |
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor | Reliable signal | NCT06174779: Percent change in body weight from baseline at Week 40: -9.75% (efpeglenatide/HM11260C) vs -0.95% (placebo); least-squares mean difference -8.13 percentage points, statistically significant | |
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Eloralintide | Phase 3 | Peptide | Amylin receptor | Reliable signal | NCT06230523: Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%. | |
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | Reliable signal | NCT06525935: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) | |
| HDM1002 | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lenbelintide | Phase 3 | Peptide | Amylin receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Maridebart Cafraglutide (MariTide) | Phase 3 | Peptide | GLP-1R agonist; GIPR antagonist | Reliable signal | NCT05669599: Primary endpoint percent change in body weight baseline to week 52 (treatment policy estimand): -12.3% to -16.2% across doses vs -2.5% placebo (obesity cohort); -8.4% to -12.3% vs -1.7% placebo (obesity-diabetes cohort) | |
| Mazdutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Reliable signal | NCT05607680: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met. | |
| MDR-001 | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Mibavademab | Phase 3 | Monoclonal antibody | Leptin receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Olatorepatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Reliable signal | NCT06839664: Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. | |
| Petrelintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | Partial signal | NCT06662539: Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). | |
| RAY1225 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Retatrutide | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | Partial signal | NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. NCT05931367: Co-primary 1, WOMAC pain subscale change to week 68 (treatment-regimen estimand): retatrutide 9 mg -4.0 points (-67.2%), 12 mg -3.7 points (-62.6%) vs placebo -2.1 points (-35.1%); statistically significant for each dose per the sponsor (p not printed), met. Co-primary 2, percent change in body weight to week 68: 9 mg -20.0%, 12 mg -23.7% vs placebo -4.6%; statistically significant for each dose per the sponsor (p not printed), met. | |
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Reliable signal | NCT06396429: Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss | |
| Safiglipron (HRS-7535) | Phase 3 | Small molecule | GLP-1 receptor | Reliable signal | NCT06904105: Percent body-weight change at week 44, treatment-policy estimand (prespecified primary): -8.0% (120 mg) and -9.8% (180 mg) vs -2.4% placebo, superiority stated as met (no p-value given). Proportion with at least 5% weight loss at week 44 (registry primary): 58.6% (120 mg) and 68.2% (180 mg); placebo rate and significance not reported. | |
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT06066515: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). NCT06066528: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo). | |
| Tesofensine | Phase 3 | Small molecule | Noradrenaline/dopamine/serotonin reuptake | Reliable signal | NCT00394667: After 24 weeks, mean weight loss with diet and placebo was 2.0%, while tesofensine doses produced significantly greater reductions of 4.5%, 9.2% and 10.6% respectively. | |
| UBT251 | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| VCT220 | Phase 3 | Small molecule | GLP-1 receptor | Partial signal | NCT06939296: Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). NCT07011797: Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding. | |
| VK2735 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | Reliable signal | NCT06828055: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 | |
| Zenagamtide | Phase 3 | Peptide | GLP-1/amylin receptor (dual) | Weak signal | NCT06064006: Primary outcome, safety (number of treatment-emergent adverse events; no formal efficacy test). Secondary endpoint, estimated mean bodyweight change vs placebo: -24.3% vs -1.1% at week 36 (60 mg), -22.0% vs 1.9% (20 mg, week 36), -16.2% vs 2.3% (5 mg, week 28), -9.7% vs 2.0% (1.25 mg, week 20); p<0.0001 (Parts A-D), p=0.0003 (Part E) (Lancet 2025). | |
| Zovaglutide | Phase 3 | Peptide | GLP-1 receptor | Reliable signal | NCT07020884: Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001. | |
| Efsubaglutide Alfa | Phase 2/3 | Protein / enzyme therapeutic | GLP-1 receptor | Partial signal | NCT06732960: Efsubaglutide Alfa produced a mean weight reduction of 7.16% (95% CI: -8.08 to -6.24) versus 0.86% with placebo. Overall, 82.5% of Efsubaglutide-treated participants achieved >=5% weight loss (vs. 0% placebo). | |
| ABBV-295 | Phase 2 | Peptide | Amylin receptor | Weak signal | Featured results are safety only in this race | |
| Apitegromab (Isembyld) | Phase 2 | Monoclonal antibody | Myostatin (pro/latent form) | Partial signal | NCT06445075: Change from baseline in total Lean Body Mass at 24 weeks: -1.6 kg (-3.4 lbs) with apitegromab+tirzepatide vs -3.5 kg (-7.6 lbs) with placebo+tirzepatide; difference 1.9 kg (4.2 lbs) less lean-mass loss with apitegromab, i.e. 54.9% relative preservation (p=0.001). | |
| ARD-101 | Phase 2 | Small molecule | Bitter taste receptor (gut) | Partial signal | NCT05121441: General-obesity Phase 2 (n=20): ARD-101 produced a 2.51-fold greater reduction in hunger rating (Control of Eating Questionnaire) vs placebo; p=0.015 | |
| AT-7687 | Phase 2 | Peptide | GIPR antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| AZD9550 | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | No reviewed efficacy summary in this indication | |
| BGM1812 | Phase 2 | Peptide | Amylin/calcitonin receptor (dual) | Weak signal | NCT07224399: Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026) | |
| BI 3034701 | Phase 2 | Peptide | GLP-1/GIP/NPY2 receptor (triple) | Weak signal | No reviewed efficacy summary in this indication | |
| Bimagrumab | Phase 2 | Monoclonal antibody | Activin/myostatin type II receptor | Partial signal | NCT05616013: Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17) | |
| Bremelanotide (Vyleesi) | Phase 2 | Peptide | MC4R | Reliable signal | NCT06565611: BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001. | |
| Dapiglutide | Phase 2 | Peptide | GLP-1/GLP-2 receptor (dual) | Partial signal | NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed | |
| ECC4703 | Phase 2 | — | Thyroid hormone receptor beta (THRβ) | not yet graded | No reviewed efficacy summary in this indication | |
| Ecnoglutide (VRB-101) | Phase 2 | Peptide | GLP-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Enobosarm | Phase 2 | Small molecule | Androgen receptor (selective) | Partial signal | NCT06282458: Change in total lean body mass at 16 weeks (day 112), enobosarm+semaglutide vs placebo+semaglutide: 71% relative reduction in lean mass loss (p=0.002); 27% greater fat loss vs control | |
| ERX1000 | Phase 2 | Small molecule | Leptin | Weak signal | No reviewed efficacy summary in this indication | |
| Garetosmab (Pasatru) | Phase 2 | Monoclonal antibody | Activin A | not yet graded | No reviewed efficacy summary in this indication | |
| HM15275 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | Weak signal | Featured results are safety only in this race | |
| HRS-4729 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | Weak signal | Featured results are safety only in this race | |
| LAE102 | Phase 2 | Monoclonal antibody | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary in this indication | |
| Macupatide | Phase 2 | Peptide | GIP receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Metreleptin (Myalept) | Phase 2 | Protein / enzyme therapeutic | Leptin | Partial signal | No reviewed efficacy summary in this indication | |
| NA-931 | Phase 2 | Peptide | GLP-1/GIP/glucagon/IGF-1 receptors (quadruple) | Partial signal | NCT06564753: Mean body weight reduction from baseline at Week 13: up to 13.8% at the 150 mg daily dose; 11.9% relative to placebo | |
| Nimacimab | Phase 2 | Monoclonal antibody | CB1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| NNC0519-0130 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | Partial signal | No reviewed efficacy summary in this indication | |
| NNC0662-0419 | Phase 2 | Peptide | GLP-1 / GIP / Amylin receptors | Weak signal | No reviewed efficacy summary in this indication | |
| Orlistat / Acarbose (EMP16) | Phase 2 | Small molecule | GI lipase + intestinal alpha-glucosidase | Partial signal | No reviewed efficacy summary in this indication | |
| THDBH120 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | Weak signal | Featured results are safety only in this race | |
| Brenipatide | Phase 1 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| KP405 | Phase 1(overall) | Peptide | GLP-1/GIP receptor (dual) | Partial signal(overall) | No reviewed efficacy summary in this indication |
Large race: only the 71 furthest-along competitors are listed; 48 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
3 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow HDM1005 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.